AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37988638 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction pembrolizumab (200 mg, once every 21 days) followed by risk-adapted thoracic radiotherapy (55 Gy for tumors or lymph nodes >20 cc, 48 Gy for smaller lesions) and consolidation pembrolizumab for 1 year.
Number of subjects: 25
Study 37988638 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction pembrolizumab (200 mg, once every 21 days)
Number of subjects: 25
Study 37988638 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted thoracic radiotherapy
Number of subjects: 25
Study 37988648 — intervention group
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin (DV) 2 mg/kg IV infusion, once every 2 weeks
Number of subjects: 107
Study 37988814 — intervention group
Group type: EXPERIMENTAL
Intervention: SpHb-guided management
Number of subjects: 130
Study 37988814 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 130
Study 37988846 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Pulmonary Embolism Shock (CPES) score > 3
Number of subjects: 848
Study 37988846 — intervention group
Group type: EXPERIMENTAL
Intervention: CPES score > 4
Number of subjects: 848
Study 37988846 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic RV enlargement instead of echocardiographic RV dysfunction
Number of subjects: 848
Study 37988846 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of intermediate-risk PE
Number of subjects: 848
Study 37989134 — intervention group
Group type: EXPERIMENTAL
Intervention: Latin dance intervention
Number of subjects: 330
Study 37989134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity
Number of subjects: 330
Study 37989134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity and total physical activity
Number of subjects: 330
Study 37989142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 micrograms every 3 hours for up to five doses)
Number of subjects: 2546
Study 37989142 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (100 micrograms every 4 hours for up to two doses)
Number of subjects: 2546
Study 37989142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 2546
Study 37989142 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 2546
Study 37989361 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention alone
Number of subjects: 294
Study 37989361 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention integrated with personal medical nutrition therapy
Number of subjects: 294
Study 37989361 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 294
Study 37989362 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time electronic heart team decision-making approach
Number of subjects: 490
Study 37989362 — intervention group
Group type: COMPARATOR
Intervention: Conventional heart team approach
Number of subjects: 490
Study 37989369 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 264
Study 37989369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperandrogenism
Number of subjects: 264
Study 37989369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 37989370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical softening measured with the Pregnolia System
Number of subjects: 390
Study 37989370 — intervention group
Group type: COMPARATOR
Intervention: Cervical length measurement and fetal fibronectin test (not specified if used in combination)
Number of subjects: 390
Study 37989376 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Clinic (CP@clinic) programme
Number of subjects: 41
Study 37989381 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-antiplatelet therapy (SAPT) with aspirin 75-100 mg for 6 months
Number of subjects: 650
Study 37989381 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC) with warfarin, therapeutic international normalised ratio at 1.8-2.5 for 6 months
Number of subjects: 650
Study 37989482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m²) in combination with paclitaxel and carboplatin
Number of subjects: 18
Study 37989482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (25 mg/m² or 30 mg/m²) in combination with paclitaxel and carboplatin
Number of subjects: 18
Study 37989586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Corrective Messaging (NCM)
Number of subjects: 794
Study 37989586 — intervention group
Group type: COMPARATOR
Intervention: No message control
Number of subjects: 794
Study 37989710 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 89
Study 37989710 — intervention group
Group type: COMPARATOR
Intervention: WMH (white matter hyperintensity)
Number of subjects: 89
Study 37989943 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 104
Study 37989943 — intervention group
Group type: COMPARATOR
Intervention: Balanced crystalloid solution (Plasma-Lyte)
Number of subjects: 104
Study 37990160 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-assisted hand motor imagery (MI) training
Number of subjects: 30
Study 37990160 — intervention group
Group type: COMPARATOR
Intervention: Hand motor imagery (MI) training not supported by BCI
Number of subjects: 30
Study 37990162 — intervention group
Group type: EXPERIMENTAL
Intervention: isatuximab-RVd
Number of subjects: 179
Study 37990162 — intervention group
Group type: EXPERIMENTAL
Intervention: elotuzumab-RVd
Number of subjects: 179
Study 37990162 — intervention group
Group type: EXPERIMENTAL
Intervention: RVd (6 cycles of 21 days)
Number of subjects: 179
Study 37990162 — intervention group
Group type: COMPARATOR
Intervention: RVd (general)
Number of subjects: 179
Study 37990163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic motor activation (TOMAC) sessions for 30 minutes bilaterally over the peroneal nerve when RLS symptoms presented.
Number of subjects: 20
Study 37990173 — intervention group
Group type: COMPARATOR
Intervention: Light hypnosis (non-drug intervention) in healthy controls (CTRL)
Number of subjects: 126
Study 37990173 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG microstate anomalies
Number of subjects: 126
Study 37990202 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping through saliva samples submitted by participants with ARFID
Number of subjects: 3000
Study 37990202 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive online consent and phenotyping
Number of subjects: 3000
Study 37990223 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR cut-off ≥ 7.95
Number of subjects: 5034
Study 37990224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-mucosal injection of vitamin C (L-Ascorbic acid 1000 mg/5 ml)
Number of subjects: 26
Study 37990224 — intervention group
Group type: COMPARATOR
Intervention: Diode laser (980 nm, 1.5 W, continuous wave mode)
Number of subjects: 26
Study 37990224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 37990250 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth behaviour change support (BCS) program
Number of subjects: 78
Study 37990252 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 minutes of class-scheduled physical activity and physical education per week for 9 months (Intervention schools n=19)
Number of subjects: 1370
Study 37990252 — intervention group
Group type: COMPARATOR
Intervention: Normal 2 hours of weekly physical education (Control schools n=9)
Number of subjects: 1370
Study 37990322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough and Sputum Assessment Questionnaire (CASA-Q)
Number of subjects: 48
Study 37990323 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS SD-SF-8b
Number of subjects: 1022
Study 37990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation facilitation (IF) for IPV screening programs over 6 months with external and internal facilitators.
Number of subjects: 8
Study 37990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection using the i-PARIHS framework through interviews with key informants.
Number of subjects: 8
Study 37990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data on IPV screening uptake from medical records and surveys.
Number of subjects: 8
Study 37990359 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidneys from donors with acute kidney injury (AKI)
Number of subjects: 0
Study 37990359 — intervention group
Group type: COMPARATOR
Intervention: Kidneys from non-AKI donors
Number of subjects: 0
Study 37990636 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered tones linked to brainwaves (LB)
Number of subjects: 106
Study 37990636 — intervention group
Group type: COMPARATOR
Intervention: Random engineered tones not linked to brainwaves (NL, sham control)
Number of subjects: 106
Study 37990636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LB and NL groups
Number of subjects: 106
Study 37990636 — intervention group
Group type: EXPERIMENTAL
Intervention: LB and NL groups
Number of subjects: 106
Study 37990670 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30% protein, 30% fat, 40% carbohydrate)
Number of subjects: 12
Study 37990670 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet (15% protein, 30% fat, 55% carbohydrate)
Number of subjects: 12
Study 37990670 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 12
Study 37990929 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 89
Study 37990929 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 89
Study 37991022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 151
Study 37991022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L questionnaire at 12 months after hospitalization for COVID-19
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L questionnaire at 3, 6, and 9 months after hospitalization for COVID-19
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work or education
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: New disabilities in instrumental activities of daily living
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptoms
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization
Number of subjects: 611
Study 37991122 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 611
Study 37991178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral Neuromodulation (SNM)
Number of subjects: 67
Study 37991178 — intervention group
Group type: COMPARATOR
Intervention: Personalized Conservative Treatment (PCT)
Number of subjects: 67
Study 37991265 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life with a Ventricular Assist Device questionnaire
Number of subjects: 393
Study 37991508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac computed tomography (CT)
Number of subjects: 3445
Study 37991508 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 3445
Study 37991639 — intervention group
Group type: EXPERIMENTAL
Intervention: ABY-025 (Affibody molecule)
Number of subjects: 0
Study 37991639 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cGMP-compliant radiosynthesis method
Number of subjects: 0
Study 37991657 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication optimization intervention
Number of subjects: 285
Study 37991657 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication optimization intervention (non-long stayers)
Number of subjects: 285
Study 37991657 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication optimization intervention (long stayers)
Number of subjects: 285
Study 37991657 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 285
Study 37991693 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P43
Number of subjects: 509
Study 37991693 — intervention group
Group type: COMPARATOR
Intervention: Originator ustekinumab
Number of subjects: 509
Study 37991693 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P43 and Originator ustekinumab
Number of subjects: 509
Study 37991697 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 37991697 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 37991697 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37991745 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated DAPT (immediate DAPT discontinuation, followed by single APT for ≥6 months)
Number of subjects: 4579
Study 37991745 — intervention group
Group type: COMPARATOR
Intervention: Standard DAPT (DAPT for ≥2 additional months, followed by single APT for 11 months)
Number of subjects: 4579
Study 37991745 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated DAPT
Number of subjects: 4579
Study 37991761 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM-guided approach (group 1)
Number of subjects: 170
Study 37991761 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (group 2)
Number of subjects: 170
Study 37991778 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant carboplatin (AUC 6) and docetaxel (75 mg/m2) plus pembrolizumab (200 mg) every 21 days for 6 cycles
Number of subjects: 115
Study 37991835 — intervention group
Group type: EXPERIMENTAL
Intervention: CO monitoring for guidance of intraoperative fluid therapy and low-dose dobutamine infusion (2.5 μg/kg/hr) for up to 4 hours postoperatively.
Number of subjects: 34
Study 37991835 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-directed fluid therapy with low-dose dobutamine infusion.
Number of subjects: 34
Study 37991835 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (current practice without CO monitoring and dobutamine infusion).
Number of subjects: 34
Study 37991839 — intervention group
Group type: EXPERIMENTAL
Intervention: Spark (v1.0), a 5-week, self-guided, CBT-based digital program using a mobile app and VR experiences
Number of subjects: 30
Study 37991839 — intervention group
Group type: EXPERIMENTAL
Intervention: Spark program
Number of subjects: 30
Study 37991939 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (6 vs 3 years after 2 to 3 years of adjuvant tamoxifen)
Number of subjects: 1781
Study 37991939 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (extended)
Number of subjects: 1781
Study 37992000 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of RSVpreF and SIIV
Number of subjects: 1403
Study 37992000 — intervention group
Group type: COMPARATOR
Intervention: SIIV administered alone
Number of subjects: 1403
Study 37992000 — intervention group
Group type: COMPARATOR
Intervention: RSVpreF administered alone
Number of subjects: 1403
Study 37992063 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded card containing treatment details
Number of subjects: 20
Study 37992063 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative drug packaging to conceal drug identity
Number of subjects: 20
Study 37992063 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer refills to cover travel periods
Number of subjects: 20
Study 37992063 — intervention group
Group type: EXPERIMENTAL
Intervention: Health delivery improvements
Number of subjects: 20
Study 37992138 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 20
Study 37992138 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary surgery
Number of subjects: 20
Study 37992183 — intervention group
Group type: EXPERIMENTAL
Intervention: Novavax protein-based COVID-19 vaccine (NVX-CoV2373)
Number of subjects: 0
Study 37992183 — intervention group
Group type: COMPARATOR
Intervention: mRNA-based boosters (BNT162b2 and mRNA-1273)
Number of subjects: 0
Study 37992203 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment initiation
Number of subjects: 200
Study 37992203 — intervention group
Group type: COMPARATOR
Intervention: Standard of care referral to outpatient care
Number of subjects: 200
Study 37992261 — intervention group
Group type: EXPERIMENTAL
Intervention: R-maintenance (Rituximab maintenance)
Number of subjects: 0
Study 37992261 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha maintenance
Number of subjects: 0
Study 37992261 — intervention group
Group type: COMPARATOR
Intervention: R-FC (Rituximab, fludarabine, cyclophosphamide)
Number of subjects: 0
Study 37992261 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 0
Study 37992261 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD monitoring by qPCR
Number of subjects: 0
Study 37992970 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 1.0 g⋅kg
Number of subjects: 16
Study 37992970 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intakes ranging from 0.6 to 1.5 g⋅kg
Number of subjects: 16
Study 37993030 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable, app-controlled, transcutaneous electrical nerve stimulation (TENS) device
Number of subjects: 142
Study 37993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 1000 mg at week 12
Number of subjects: 170
Study 37993033 — intervention group
Group type: COMPARATOR
Intervention: Placebo at week 12
Number of subjects: 170
Study 37993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab (any dose) at 1 year
Number of subjects: 170
Study 37993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab (any dose) at 1 year based on week 12 response
Number of subjects: 170
Study 37993058 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training module (OPTIC-IBD) including 24 educational videos on IBD colonic lesions, with a final assessment after 60 days.
Number of subjects: 117
Study 37993058 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training module (OPTIC-IBD)
Number of subjects: 117
Study 37993058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 117
Study 37993062 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff Vision-assisted colonoscopy (EVC)
Number of subjects: 717
Study 37993062 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 717
Study 37993062 — intervention group
Group type: COMPARATOR
Intervention: 2 × CC
Number of subjects: 717
Study 37993062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × EVC
Number of subjects: 717
Study 37993149 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200 or 300 mg daily in a 3-weekly cycle)
Number of subjects: 84
Study 37993149 — intervention group
Group type: COMPARATOR
Intervention: Active symptom control (ASC)
Number of subjects: 84
Study 37993149 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 84
Study 37993156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing guided by the CARV protocol
Number of subjects: 0
Study 37993156 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice (control group)
Number of subjects: 0
Study 37993168 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic device (ALBA) with regular treatment
Number of subjects: 32
Study 37993168 — intervention group
Group type: COMPARATOR
Intervention: Regular rehabilitation only
Number of subjects: 32
Study 37993169 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-powered tool using wearable sensors for pain assessment
Number of subjects: 15
Study 37993169 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 15
Study 37993199 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DVUS imaging assessments of peripheral arteries
Number of subjects: 3471
Study 37993199 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher low-density lipoprotein cholesterol (LDL-C) and elevated systolic blood pressure (SBP)
Number of subjects: 3471
Study 37993201 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 529
Study 37993203 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning algorithms (Lasso regression, gradient boosting)
Number of subjects: 1800
Study 37993203 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models
Number of subjects: 1800
Study 37993203 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning-based approach
Number of subjects: 1800
Study 37993279 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity non-invasive ventilation (HI-NIV) during exercise training (ET)
Number of subjects: 26
Study 37993279 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 26
Study 37993355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial
Number of subjects: 699
Study 37993525 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 79
Study 37993525 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 79
Study 37993549 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized virtual reality naturalistic scenarios
Number of subjects: 23
Study 37993560 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC-OX
Number of subjects: 342
Study 37993560 — intervention group
Group type: COMPARATOR
Intervention: Primary tumor surgery
Number of subjects: 342
Study 37993666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid telerehabilitation group (Pilates-based exercises with synchronous sessions)
Number of subjects: 32